These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16236895)

  • 21. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ
    Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension.
    Nishikawa-Takahashi M; Ueno S; Kario K
    Life Sci; 2014 Nov; 118(2):410-3. PubMed ID: 24690389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
    Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC
    Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension.
    Souza R; Jardim C; Martins B; Cortopassi F; Yaksic M; Rabelo R; Bogossian H
    Curr Med Res Opin; 2005 Jun; 21(6):907-11. PubMed ID: 15969891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
    Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
    Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
    Sharma S; Kashour T; Philipp R
    Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA; Rogers P; Li W; Harries C; Cramer D; Ward S; Mikhail GW; Gibbs JS
    Int J Cardiol; 2005 Jan; 98(1):147-51. PubMed ID: 15676179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.
    Toshner MR; Gopalan D; Suntharalingam J; Treacy C; Soon E; Sheares KK; Morrell NW; Screaton N; Pepke-Zaba J
    J Heart Lung Transplant; 2010 Jun; 29(6):610-5. PubMed ID: 20227301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.
    Leuchte HH; Holzapfel M; Baumgartner RA; Neurohr C; Vogeser M; Behr J
    Chest; 2005 Oct; 128(4):2368-74. PubMed ID: 16236896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
    Schulze-Neick I; Gilbert N; Ewert R; Witt C; Gruenig E; Enke B; Borst MM; Lange PE; Hoeper MM
    Am Heart J; 2005 Oct; 150(4):716. PubMed ID: 16209972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.
    Skoro-Sajer N; Bonderman D; Wiesbauer F; Harja E; Jakowitsch J; Klepetko W; Kneussl MP; Lang IM
    J Thromb Haemost; 2007 Mar; 5(3):483-9. PubMed ID: 17319903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
    Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
    Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.